Aurinia Pharmaceuticals Inc [NASDAQ: AUPH] closed the trading session at $7.88 on 11/02/23. The day’s price range saw the stock hit a low of $7.51, while the highest price level was $8.16. The company report on November 2, 2023 at 6:00 PM that Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis.
Patients treated with LUPKYNISⓇ in a repeat kidney biopsy sub-study achieved improvement in histologic activity with stable chronicity scores and no evidence of chronic injury.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
A propensity analysis of AURORA 1 suggested that LUPKYNISⓇ plus standard of care improved safety and demonstrated earlier reductions in proteinuria when compared to a conventional regimen consisting of higher doses of both glucocorticoids and mycophenolate mofetil.
The stocks have a year to date performance of 82.41 percent and weekly performance of 7.50 percent. The stock has been moved at -30.51 percent over the last six months. The stock has performed 9.60 percent around the most recent 30 days and changed -19.76 percent over the most recent 3-months.
If compared to the average trading volume of 1.91M shares, AUPH reached to a volume of 3179690 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Aurinia Pharmaceuticals Inc [AUPH]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AUPH shares is $14.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AUPH stock is a recommendation set at 1.62. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Aurinia Pharmaceuticals Inc shares, keeping their opinion on the stock as Perform, with their previous recommendation back on November 04, 2022.
The Average True Range (ATR) for Aurinia Pharmaceuticals Inc is set at 0.40, with the Price to Sales ratio for AUPH stock in the period of the last 12 months amounting to 7.06. The Price to Book ratio for the last quarter was 2.88, with the Price to Cash per share for the same quarter was set at 2.45.
AUPH stock trade performance evaluation
Aurinia Pharmaceuticals Inc [AUPH] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.50. With this latest performance, AUPH shares gained by 9.60% in over the last four-week period, additionally sinking by -30.51% over the last 6 months – not to mention a drop of -1.62% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AUPH stock in for the last two-week period is set at 54.14, with the RSI for the last a single of trading hit 61.15, and the three-weeks RSI is set at 49.56 for Aurinia Pharmaceuticals Inc [AUPH]. The present Moving Average for the last 50 days of trading for this stock 8.20, while it was recorded at 7.38 for the last single week of trading, and 9.49 for the last 200 days.
Aurinia Pharmaceuticals Inc [AUPH]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Aurinia Pharmaceuticals Inc [AUPH] shares currently have an operating margin of -84.30 and a Gross Margin at +95.77. Aurinia Pharmaceuticals Inc’s Net Margin is presently recorded at -80.71.
Return on Total Capital for AUPH is now -25.07, given the latest momentum, and Return on Invested Capital for the company is -24.06. Return on Equity for this stock declined to -24.46, with Return on Assets sitting at -21.33. When it comes to the capital structure of this company, Aurinia Pharmaceuticals Inc [AUPH] has a Total Debt to Total Equity ratio set at 1.99. Additionally, AUPH Total Debt to Total Capital is recorded at 1.96, with Total Debt to Total Assets ending up at 1.72. Long-Term Debt to Equity for the company is recorded at 1.76, with the Long-Term Debt to Total Capital now at 1.73.
Reflecting on the efficiency of the workforce at the company, Aurinia Pharmaceuticals Inc [AUPH] managed to generate an average of -$360,600 per employee. Receivables Turnover for the company is 9.28 with a Total Asset Turnover recorded at a value of 0.26.Aurinia Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.21 and a Current Ratio set at 6.75.
Aurinia Pharmaceuticals Inc [AUPH]: Institutional Ownership
The top three institutional holders of AUPH stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in AUPH stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in AUPH stock with ownership which is approximately 5.7994%.
